Valuation: Abpro Corporation

Market Cap 1.17M 1.03M 953K 877K 1.66M 112M 1.69M 11.36M 4.46M 55.15M 4.41M 4.31M 190M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 1.25M 1.1M 1.02M 937K 1.77M 120M 1.81M 12.13M 4.76M 58.91M 4.71M 4.6M 203M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.31M
+0.44%+1.41%+4.36%+10.81% 50.73B
-1.57%-3.18%+383.82%+593.37% 39.73B
-0.14%+0.77%+27.49%-5.50% 34.69B
+1.76%-1.78%+21.44%+53.38% 33.21B
-0.06%-0.45%+2.94%+28.70% 26.76B
-1.93%-1.01% - - 16.8B
-1.49%-6.18%+63.89%+120.53% 15.37B
+0.78%+1.16%+14.69%+17.32% 13.78B
-0.97%-2.83%+10.35%-33.29% 12.85B
Average -0.32%-0.96%+66.12%+98.16% 27.1B
Weighted average by Cap. -0.18%-0.35%+81.60%+123.89%

Financials

2024 2025
Net sales 183K 161K 149K 137K 259K 17.52M 264K 1.77M 695K 8.6M 687K 672K 29.7M -
Net income -7.23M -6.34M -5.87M -5.41M -10.22M -692M -10.42M -70.02M -27.46M -340M -27.16M -26.56M -1.17B -2.89M -2.54M -2.35M -2.16M -4.09M -277M -4.17M -28M -10.98M -136M -10.86M -10.62M -469M
Net Debt 478K 419K 388K 357K 676K 45.75M 689K 4.63M 1.82M 22.47M 1.79M 1.76M 77.59M 80K 70.17K 64.99K 59.8K 113K 7.66M 115K 775K 304K 3.76M 300K 294K 12.99M
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-